Effect of adalimumab on quality of life in patients with active ankylosing spondylitis
Objective To evaluate the efficacy of adalimumab in improving the quality of life of adult patients with active ankylosing spondylitis （AS）. Methods This was a post-hoc study of the randomized，double-blind controlled clinical trial of adalimumab and placebo in AS patients. In this clinical trial，AS...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of New Medicine
2023-06-01
|
| Series: | Xin yixue |
| Subjects: | |
| Online Access: | https://www.xinyixue.cn/fileup/0253-9802/PDF/1689304283637-77366800.pdf |
| _version_ | 1797780559003385856 |
|---|---|
| author | Cao Shuangyan, Shao Zhanqin, Gu Jieruo |
| author_facet | Cao Shuangyan, Shao Zhanqin, Gu Jieruo |
| author_sort | Cao Shuangyan, Shao Zhanqin, Gu Jieruo |
| collection | DOAJ |
| description | Objective To evaluate the efficacy of adalimumab in improving the quality of life of adult patients with active ankylosing spondylitis （AS）. Methods This was a post-hoc study of the randomized，double-blind controlled clinical trial of adalimumab and placebo in AS patients. In this clinical trial，AS patients were randomly divided into the 12-week adalimumab and placebo groups according to the proportion of 2∶1. In the adalimumab group，AS patients were treated with adalimumab at a single dose of 40 mg，once every two weeks. The SF-36 Quality of Life Questionnaire was distributed to patients to self-evaluate health status before and at the 12th week after medication，respectively. Results AS patients in the adalimumab group obtained significant improvement in the scores of physiological functioning，bodily pain and social functioning compared with their counterparts in the placebo group （all P < 0.05）. In the adalimumab group，the scores of physical functioning，role-playing physical functioning，bodily pain，overall health，vitality and social functioning after 12-week medication therapy were improved compared with the baseline scores（all P < 0.05）. Conclusion Adalimumab is beneficial to enhancing the quality of life of adult patients with active AS. |
| first_indexed | 2024-03-12T23:45:38Z |
| format | Article |
| id | doaj.art-b92908547e56477d9ce10d4f6505827c |
| institution | Directory Open Access Journal |
| issn | 0253-9802 |
| language | zho |
| last_indexed | 2024-03-12T23:45:38Z |
| publishDate | 2023-06-01 |
| publisher | Editorial Office of Journal of New Medicine |
| record_format | Article |
| series | Xin yixue |
| spelling | doaj.art-b92908547e56477d9ce10d4f6505827c2023-07-14T09:53:22ZzhoEditorial Office of Journal of New MedicineXin yixue0253-98022023-06-0154643243610.3969/j.issn.0253-9802.2023.06.011Effect of adalimumab on quality of life in patients with active ankylosing spondylitisCao Shuangyan, Shao Zhanqin, Gu Jieruo0Department of Rheumatology and Immunology，the Seventh Affiliated Hospital of Sun Yat-sen University，Shengzhen 517108，ChinaObjective To evaluate the efficacy of adalimumab in improving the quality of life of adult patients with active ankylosing spondylitis （AS）. Methods This was a post-hoc study of the randomized，double-blind controlled clinical trial of adalimumab and placebo in AS patients. In this clinical trial，AS patients were randomly divided into the 12-week adalimumab and placebo groups according to the proportion of 2∶1. In the adalimumab group，AS patients were treated with adalimumab at a single dose of 40 mg，once every two weeks. The SF-36 Quality of Life Questionnaire was distributed to patients to self-evaluate health status before and at the 12th week after medication，respectively. Results AS patients in the adalimumab group obtained significant improvement in the scores of physiological functioning，bodily pain and social functioning compared with their counterparts in the placebo group （all P < 0.05）. In the adalimumab group，the scores of physical functioning，role-playing physical functioning，bodily pain，overall health，vitality and social functioning after 12-week medication therapy were improved compared with the baseline scores（all P < 0.05）. Conclusion Adalimumab is beneficial to enhancing the quality of life of adult patients with active AS.https://www.xinyixue.cn/fileup/0253-9802/PDF/1689304283637-77366800.pdf|active ankylosing spondylitis|adalimumab|quality of life|adult|sf-36 quality of life questionnaire |
| spellingShingle | Cao Shuangyan, Shao Zhanqin, Gu Jieruo Effect of adalimumab on quality of life in patients with active ankylosing spondylitis Xin yixue |active ankylosing spondylitis|adalimumab|quality of life|adult|sf-36 quality of life questionnaire |
| title | Effect of adalimumab on quality of life in patients with active ankylosing spondylitis |
| title_full | Effect of adalimumab on quality of life in patients with active ankylosing spondylitis |
| title_fullStr | Effect of adalimumab on quality of life in patients with active ankylosing spondylitis |
| title_full_unstemmed | Effect of adalimumab on quality of life in patients with active ankylosing spondylitis |
| title_short | Effect of adalimumab on quality of life in patients with active ankylosing spondylitis |
| title_sort | effect of adalimumab on quality of life in patients with active ankylosing spondylitis |
| topic | |active ankylosing spondylitis|adalimumab|quality of life|adult|sf-36 quality of life questionnaire |
| url | https://www.xinyixue.cn/fileup/0253-9802/PDF/1689304283637-77366800.pdf |
| work_keys_str_mv | AT caoshuangyanshaozhanqingujieruo effectofadalimumabonqualityoflifeinpatientswithactiveankylosingspondylitis |